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Abstract 
Background: Yemen faces major challenges in improving the health status of its population 
as it is entering an epidemiological transition with rising non- communicable diseases e.g. 
obesity, diabetes and cardiovascular diseases (CVDs). We designed this study to find out the 
prevalence of Metabolic Syndrome (MS) and its components among obese Yemeni patients.  
 
Methods: All obese (waist circumference >102 cm (40 inch) in male and >88 cm (35 inch) 
in female) attending the outpatients medical clinics at the three teaching hospitals in Sana'a 
city,  were  examined  and  their  blood  pressure  (BP),  fasting  samples  of  plasma  glucose, 
triglycerides, and HDL cholesterol were measured. The prevalence of MS obtained based on 
the Adult Treatment Panel III and presence of at least 3 of the following: systolic BP ≥130 
mm Hg and/or diastolic BP ≥ 85 mm Hg or on treatment for high BP, fasting glucose ≥110 
mg/dl or on diabetes treatment, triglycerides ≥150 mg/dl, and HDL cholesterol <40 mg/dl in 
men and <50 mg/dl in women.   
 
Results: 200 obese were identified during study period with an overall MS prevalence of 
46%. The metabolic co-morbidities were raised BP (68%), high triglycerides (66%), reduced 
high density lipoprotein (64%), and raised fasting blood glucose (40%). 
 
Conclusion: Prevalence of MS is high among obese Yemeni patients and high BP was the 
commonest co-morbidity. These findings highlight an urgent need to develop strategies for 
prevention,  detection,  and treatment  of MS that could  contribute to decreasing  the rising 
incidence of CVD and diabetes.                           
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Introduction: 
Epidemiological  studies  worldwide  indicate  that  obesity  is  currently  the  most  common 
metabolic disease in the world. The World Health Organization (WHO) estimates that there 
are approximately 350 million obese people (Body Mass Index (BMI) ≥30.0) and over 1 
billion overweight people (BMI ≥25) in the world. Overweight and obesity are major risk 
factors  for  a  number  of  chronic  diseases,  including  diabetes,  cardiovascular  diseases  and 
cancer. Over all about 2.5 million deaths are attributed to overweight/obesity worldwide [1]. 
Metabolic Syndrome (MS); also  referred to  as  Syndrome X or  Insulin  Resistance 
Syndrome; describes a cluster of cardiovascular diseases (CVDs) risk factors and metabolic 
alterations associated with excess fat weight.  The MS which is  associated with threefold 
increase in type 2-diabetes and twofold increase in cardiovascular diseases has become major 
public  health  challenge  around  the  world  [2,3,4,5,6].  The  incidence  of  MS  is  rising 
worldwide which is partly due to significant increase in the prevalence of obesity [7, 8]. In 
USA, an estimated 47 million resident have MS with an overall prevalence of 24%
 [9]. In the 
Arab world, the prevalence varies widely from 17% among Palestinians in the West Bank [10] 
- using the WHO criteria- to 21% among Omani [11] and 39.3% among Saudi [12] using the 
Adult Treatment Panel (ATP III) criteria. 
Yemen is currently facing a major challenge in improving the health status of its 
population as it is entering in a period of epidemiological transition. Communicable diseases, 
such as tuberculosis, measles, and malaria, although in decline, remain high [13], while Non 
Communicable Diseases (NCDs), such as obesity, diabetes and CVDs are increasing due to 
changes in dietary behavior and more sedentary lifestyles [13, 14]. Furthermore, there is 
considerable lack of resources in the health sector. Recent Public Health Expenditure Review 
for  the  period  from  2004  to  2007  found  that  government  health  spending  declined 
substantially  over  the  four-year  period,  from  6.3%  in  2004  to  4.5%  in  2007.  Per-capita 
spending is YR 3713 (US$18.66) in 2007 which is comparatively very low. Moreover, about 
two-third of it is out-of-pocket spending by households [15]. Therefore, the implications of 
such changes in the disease pattern and demand for modern healthcare are important for 
decisions regarding health financing and allocation of resources with the rising demand for 
costly specialized services for NCDs. 
There is limited data from Yemen on these emerging NCDs [16, 17, 18], there is no 
population  based  studies  on  MS,  and  there  are  only  two  previous  published  studies  that 
investigate MS among patients with Type 2 Diabetes and patients with Chronic Hepatitis C 
[19,  20].  Both  studies  show  high  prevalence  of  MS  among  these  high  risk  groups. 
Nevertheless, these studies were conducted on the southern part of the country (Aden) but no 
previous  published  studies  from  northern  part  and  no  previous  studies  about  MS  among 
Yemeni obese patients. We designed this study to obtain the prevalence of MS and each of its 
components among obese Yemeni patients in order to stimulate further research on its actual 
prevalence both  among  the general population as well as among similar risk groups e.g. 
CVDs patients. 
 
Methods  
The study population was obese patients  (waist circumference >102 cm (40 inch) in male 
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hospitals in Sana’a City, Yemen during the study period between the 4
th of August 2007 to 
the 1
st of September 2007. Exclusion criteria were underlying endocrine diseases such as 
Cushing  disease,  acromegaly,  hypothyroidism  and  hypogonadism;  patients  on  prolonged 
steroid use and those who were on active drug treatment for obesity at the time of recruitment.  
Sample size was calculated using the formula for descriptive study (Z²×p×q)/d²) [21]. 
When the estimated prevalence of MS in obese (p) = 35%, precision error of estimation (d) = 
0.07 (or 20% of p), and alpha = 0.05, a sample size of at least 180 cases is needed to estimate 
the prevalence. It was increased by 10% to counteract any dropout/refusal. Sampling method 
is a non-probability consecutive sampling including every obese patient's came to the clinic. 
We used the ATP III published in 2001 to establish the diagnosis of MS in the study 
population that defines MS as the presence of three or more of the following risk factors: 
abdominal obesity (waist circumference >102 cm (40 inch) in male and >88 cm (35 inch) in 
female), Blood Pressure (BP) ≥130/85 mm Hg, Fasting Blood Sugar (FBS) ≥110 mg/dl (6.1 
mmol/L), triglycerides ≥150 mg/dl (1.69 mmol/L), HDL cholesterol <40 mg/dl (1.03 mmol/L) 
in male and <50 mg/dl (1.29 mmol/L) in female [22]. 
All subjects were interviewed about their age, habits, occupation, and past history of 
diabetes  and  hypertension,  as  well  as  their  drug  intake.  Subjects  underwent  a  physical 
examination consisting of the determination of waist circumference and systolic and diastolic 
blood pressure. Waist circumference was measured with a tape measure mid-way between 
the lower rib margin and the iliac crest. Blood pressure was recorded with the same mercury 
manometer  in  the  sitting  position  after  10  –  15  minutes  rest.  Each  subject  had  two 
measurements  of  blood  pressure  at  5  minutes  intervals.  Venous  blood  sampling  was 
performed  in  the  morning  after  an  overnight  fast  for  determination  of  plasma  glucose, 
triglyceride,  and  High  Density  Lipoprotein  (HDL)  cholesterol.  Laboratory  techniques  for 
biochemical analysis were glucose oxides for blood glucose, and the enzymatic method for 
triglyceride and HDL cholesterol. 
The research protocol was reviewed and approved by the Ethical Committee of the 
Faculty  of  Medicine  and  Health  Sciences,  Sana'a  University.  All  participants  provided 
informed consent after explaining the study objectives and that the data will be used only for 
purpose of the research. Health education both verbally and using education materials was 
provided to all participants and those who were found to have any medical problem were 
referred to the specialized clinic for proper management and follow up.    
Statistical  analysis  was  under  taken  using  the  statistical  package  for  the  social 
sciences (windows version 13.0; SPSS, Chicago IL USA). 
Differences  between  groups  were  tested  statistically  using  the  chi  square  test  for 
categorical and T test for numerical variables. Data were considered statistically significant 
when the p-value was ≤ 0.05.  
 
Results: 
Two hundred obese patients (60 male & 140 female) were identified during the study period. 
The  Mean  age  ±  SD  was  47.4  ±10.2  years,  with  an  age  range  of  30–77  years  with  no 
significant age difference between men and women.  
The  physical  and  metabolic  characteristic  of  the  study  population  by  gender  are 
shown in the table 1. Men have significantly higher prevalence of systolic and diastolic BP as 
well as higher FBS.  
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Table 1. The physical and metabolic characteristic of the study population by gender 
 Significant difference (p<0.05)
 
 
  The overall prevalence of the MS was 46%, with a prevalence of 45% in men and 
46.4% in women. However, there was no significant gender difference. The physical and 
metabolic characteristics of the obese patients with and without MS are shown in table 2. 
High  systolic  BP,  High  FBS,  High  triglycerides,  and  Low  HDL  were  found  to  be 
significantly associated factors of MS but age was not.  
 
Table  2.  The  physical  and  metabolic  characteristics  of  the  study  population  by 
Metabolic Syndrome 
   
 
  The highest prevalent comorbidity in patients with MS was high BP (68%), followed 
by high TG (66%), low serum HDL (64%), and raised fasting blood glucose (41%).  
 
Discussion: 
Total (n=200) 
no. (%) 
Women 
(n=140) 
no. (%) 
Men 
(n=60) 
no. (%) 
Factors 
 
95 (47.5) 
 
55 (39.3) 
 
40 (66.7)
 
 
High Systolic BP (≥130 mmHg) 
93 (46.5)  58 (41.4)  35 (58.3)
  High Diastolic BP (≥ 85 mmHg) 
30 (15)  16 (11.4)  14 (23.3)
  High FBS (≥ 110 mg/dl) 
92 (46.0)  62 (44.3)  30 (50.0)  High Triglycerides (≥150 mg/dl) 
87 (43.5)  60 (42.9)  27 (45.0) 
Low HDL: 
- males (<40 mg/dl) 
- females (<50 mg/dl) 
92 (46%)  65 (46.4%)  27 (45%)  Metabolic syndrome 
P value (95% 
Confidence 
Interval) 
Without MS 
(n=108) 
(Mean ±SD) 
With MS 
(n=92) 
(Mean ±SD) 
Total 
(n=200) 
(Mean ±SD) 
Factors 
0.2  46.5±10.8  48.4±9.3  47.4±10.2  Age (years) 
<0.0001 
(10.7:20.8) 
121.9±14.8 
 
137.7 ±21.1  129.2 ±19.6 
Systolic BP 
(mmHg) 
<0.0001 
(5.1:12.9) 
80.2±12.0 
 
89.2 ±16.2  84.3 ±14.8 
Diastolic BP 
(mmHg) 
<0.0001 
(16.6:38.2) 
82.7 ±20.7 
 
110.1 ±52.5  95.3 ±41.0  FBS (mg/dl) 
<0.0001 
(37.0:72.2) 
122.4±63.6 
 
177.0 ±62.0 
147.5±68.4 
 
Triglycerides 
(mg/dl) 
<0.0001 
(-16.8: -6.1) 
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This study analyzed the prevalence of the MS in obese patients who attended the medical 
clinics using the NCEP – ATP III criteria for definition of the metabolic syndrome. There are 
few international comparable studies of the MS among adult obese patients but we could not 
find similar studies from nearby Arabic countries among such high risk group. The several 
definitions of the syndrome that are in use (i.e. the International Diabetes Federation criteria, 
the  National  Cholesterol  Education  Program  Adult  Treatment  Panel  (NCEP  ATP)  III 
definition,  the  WHO  criteria),  makes  difficult  to  compare  prevalence  and  impact. 
Furthermore, since our study is a hospital-based study, the findings could not be generalized 
to the whole population. Nevertheless, as this is the first study about the MS from northern 
parts of Yemen among obese patients its results provide invaluable information on the MS in 
such high risk group and should encourage researchers to investigate more such an emerging, 
health problem.  
The overall prevalence of the MS among obese patients in the present study found to 
be 46% which is comparable to that found among obese patients in Taiwan (50.7%) [23] and 
France (50%) [24], slightly higher that found in  Malaysia (40.2%) [25], but still slightly 
lower than what was found in Italy obese (53%) [26]. This prevalence is higher than the 32.2 % 
prevalence that found southern part of Yemen in patients with Type 2 Diabetes [19] but lower 
than  61.97%  prevalence  among  Yemeni  patients  with  Chronic  Hepatitis  C  [20].  The 
prevalence of MS in population-based studies from the Arab world was found to be variable 
and was in the range of 17% to 45.5% [10, 12, 27, 29]. A remarkably lower prevalence found 
in population based studies from Japan [30]
 (6% using ATP III criteria) and Hong Kong [31]
 
(7.4% by the IDF criterion).  
In our study, there was no significant gender difference which is inconsistent with the 
findings from the Italian [26] and Taiwan [23] studies that found higher prevalence of the MS 
in  obese  females  which  may  be  due  to  differences  in  central  obesity.    Although  the 
prevalence from Malaysia was more in female (43.7 %) than in males (32.3 percent) the 
difference was insignificant [25]. Among Yemeni patients with  Chronic Hepatitis C [20] 
females have higher MS prevalence (69%) than males (45%) but no similar gender difference 
among type 2 Diabetic [19]. Regarding Arabian population-based studies, the findings are 
inconsistent. Some studies found that the prevalence is similar among males and females e.g. 
in Saudi Arabia [12], some found higher prevalence in females e.g. in Tunis [27], and others 
found higher prevalence among males e.g. in Lebanon [29].   
  The highest prevalent MS co morbidity in our study population was  hypertension 
(68%), followed by high TG (66%), low serum HDL (64%), and raised fasting blood glucose 
(41%). This finding was in keeping with the existing knowledge that obesity is clearly linked 
to essential hypertension. Hypertension was also the most common finding that was found 
among Malaysian [25] and Italian [26] obese and raised fasting blood glucose was the lowest 
comorbidity among Malaysian Obese
 [25]. Among Yemeni patients with type 2 diabetes, 
hypertension was also found to be the commonest comorbidity
 [19]. Low HDL cholesterol 
plays a major role in the contribution to the MS in Saudi Arabia [19]. This was explained by 
the physical inactivity, genetic predisposition, as well as dietary habits. Among Tunisian the 
hypertension was also found to be the most common comorbidity [27].    
The findings of this study demonstrate an alarming high prevalence of MS among 
Yemeni  obese  patients  as  well  as  serious  associated  comorbidities.  It  is  likely  that  the 
prevalence of MS will probably increase among Yemeni population in the coming years with Page 219 of 221                                                                         Functional Foods in Health and Disease 2011; 6:214-221  
 
expected increase in prevalence of obesity [32] due to rapidly changing life style and dietary 
habits.  
 
Conclusion: 
Our study demonstrates an alarming high prevalence of MS among obese Yemeni patients 
that increases the burden on overstrained Yemeni health system with uprising CVDs and 
other MS related health problems e.g. DM. As obesity is the main modifiable risk factor for 
MS,  raising  community  awareness  and  promotion  of  healthy  lifestyle  together  with 
organizing training course for health educators are highly recommended. There is also an 
urgent need to develop strategies for prevention, detection, and treatment of MS that could 
contribute to decreasing the incidence of grave consequences such cardiovascular disease and 
diabetes.  Meanwhile, it is  also  vital  that we obtain reliable  prevalence  among the whole 
population,  which  is  currently  lacking,  in  order  to  obtain  more  precise  estimates  of  the 
magnitude of the problem and action needed. 
 
Abbreviations:  World  Health Organization  (WHO),  Body Mass  Index (BMI), Metabolic 
Syndrome (MS), cardiovascular diseases (CVDs), Adult Treatment Panel (ATP) 
Non  Communicable  Diseases  (NCDs),  High  Density  Lipoprotein  (HDL),  Fasting  Blood 
Sugar (FBS), National Cholesterol Education Program Adult Treatment Panel (NCEP ATP), 
Ministry of Public Health and Population (MoPHP) 
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